SI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference

Rhea-AI Summary

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, a leader in musculoskeletal disorder solutions, will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference. The event features a management fireside chat on May 9, 2023, at 1:55 p.m. Eastern Time. A live webcast will be accessible via the company's website with a 90-day post-event archive available for replay.

SI-BONE, known for the iFuse Implant System, has pioneered minimally invasive surgical treatments for SI joint disorders since 2009. With nearly 80,000 procedures performed by over 3,000 surgeons, SI-BONE enjoys wide insurance coverage for these treatments. This position enables continued advancements in clinical research and the commercialization of new surgical solutions for pelvic disorders.

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 9th, 2023, at 1:55 p.m. Eastern Time / 10:55 a.m. Pacific Time.

A live webcast of each event, as well as an archived recording will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since 2009, when SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, nearly 3,000 surgeons have performed a combined total of more than 80,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two randomized controlled trials and over 120 peer reviewed publications, has enabled multiple government and private insurance payors to establish near-universal coverage of minimally invasive SI joint fusion, including many payors that cover the procedure exclusively when performed with the iFuse Implant System. Supported by this proprietary reimbursement advantage, SI-BONE has actively leveraged its market leadership position in recent years to further clinical research and evolve and commercialize novel surgical treatment solutions for SI-Joint pain, sacropelvic and pelvic fixation, and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit https://si-bone.com/.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact: 
Saqib Iqbal
saqib.iqbal@si-bone.com

FAQ

What date is SI-BONE participating in the healthcare conference?

SI-BONE will participate in the Bank of America Merrill Lynch Global Healthcare Conference on May 9, 2023.

What time will SI-BONE's fireside chat occur?

The fireside chat will take place at 1:55 p.m. Eastern Time / 10:55 a.m. Pacific Time.

Where can I watch SI-BONE's webcast of the conference?

The webcast will be available on the Investors section of SI-BONE's website.

How long will the SI-BONE conference webcast be available for replay?

The archived webcast will be available for at least 90 days after the event.

What is the iFuse Implant System by SI-BONE?

The iFuse Implant System is a minimally invasive surgical solution for treating SI joint disorders, introduced in 2009.

How many SI joint fusion procedures has SI-BONE facilitated?

SI-BONE has enabled over 80,000 SI joint fusion procedures performed by nearly 3,000 surgeons.